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The key concepts of transcriptional control were established
half a century ago in bacterial systems (Jacob and Monod,
1961). That pioneering work and many subsequent studies
established that DNA binding transcription factors (also known
as trans-factors) occupy specific DNA sequences at control
elements (cis-elements) and recruit and regulate the transcrip-
tion apparatus. In eukaryotic systems, there has been extensive
study of specific transcription factors and their cofactors, the
general transcription apparatus, and various chromatin regula-
tors, leading to a present-day consensus model for selective
gene control (Adelman and Lis, 2012; Bannister and Kouzar-
ides, 2011; Bonasio et al., 2010; Conaway and Conaway,
2011; Fuda et al., 2009; Ho and Crabtree, 2010; Roeder,
2005; Spitz and Furlong, 2012; Taatjes, 2010; Zhou et al.,
2012b).
Our knowledge of mammalian regulatory elements and the
transcriptional and chromatin regulators that operate at these
sites has increased considerably in the last decade. There
have also been substantial advances in our understanding of
the control of large portions of the gene expression program in
embryonic stem cells (ESCs) and in a number of more differenti-
ated cell types. In these relatively well-studied cells, for example,
it is now understood that a small fraction of the hundreds of tran-
scription factors that are present dominate the control of much of
the active gene expression program (Graf, 2011; Ng and Surani,
2011; Orkin and Hochedlinger, 2011; Young, 2011).
The recent insights into control of cellular gene expression
programs have had an important impact on our understanding
of misregulation of gene expression in disease. Many different
diseases and syndromes, including cancer, autoimmunity,
neurological disorders, diabetes, cardiovascular disease, and
obesity, can be caused by mutations in regulatory sequences
and in the transcription factors, cofactors, chromatin regulators,
and noncoding RNAs that interact with these regions. New
insights into the global effects of some of these mutations have
recently emerged. These insights alter our view of the underlying
cause of some diseases and are the primary focus of this
Review.We begin with a brief review of the basic features of human
genes and the fundamentals of gene regulation. This leads to
a discussion of cellular gene expression programs and the
mechanisms involved in global regulation of transcription. We
then describe how recent advances in our understanding of
the control of gene expression have led to new insights into
the mechanisms involved in misregulation of gene expression
in various human diseases and disorders.
Genes and Enhancer Elements
There are a remarkable variety and number of genes that are
transcribed into protein-coding and noncoding RNA (ncRNA)
species in mammalian cells (Table 1). The human genome is
thought to contain 20,000 protein-coding genes and at least
as many ncRNA genes (Djebali et al., 2012). Functions have
been determined or inferred for many of the protein-coding
genes, but less is understood about the functions of the ncRNA
genes.Many of the ncRNAs contribute to control of gene expres-
sion through modulation of transcriptional or posttranscriptional
processes (Bartel, 2009; Ebert and Sharp, 2012; Lee, 2012;
Orom and Shiekhattar, 2011; Rinn and Chang, 2012; Wright
and Ciosk, 2013). For example, the microRNAs (miRNAs), which
are the best studied of the various classes of ncRNAs, fine tune
the levels of target messenger RNAs (mRNAs). Some of the long
ncRNAs (lncRNAs) recruit chromatin regulators to specific
regions of the genome and thereby modify gene expression,
and some apparently do not have a function but are simply
a product of a transcriptional event that is itself regulatory (Latos
et al., 2012).
Transcription factors typically regulate gene expression by
binding enhancer elements and recruiting cofactors and
RNA polymerase II to target genes (Lelli et al., 2012; Ong and
Corces, 2011; Spitz and Furlong, 2012). Multiple transcription
factors typically bind in a cooperative fashion to individual
enhancers (Panne, 2008) and regulate transcription from the
core promoters of nearby or distant genes through physical
contacts that involve looping of the DNA between enhancers
and the core promoters (Krivega and Dean, 2012). The core
promoter elements, which include sites where transcriptionCell 152, March 14, 2013 ª2013 Elsevier Inc. 1237
Table 1. Human Genes
Class Abbreviation Function Estimated Number
Messenger RNA mRNA protein coding 20,078a
Ribosomal RNA rRNA structural and functional component of ribosome 531a
Transfer RNA tRNA translational adaptor molecule 512b
Small nuclear RNA snRNA processing of pre-mRNA 1,923a
Small nucleolar RNA snoRNA processing of rRNA, tRNA, and snRNA 1,529a
Antisense RNA aRNA gene regulation 4,424a
Long noncoding RNA lncRNA gene regulation 12,933a
MicroRNA miRNA translational inhibition and mRNA degradation >500c
Small interfering RNA siRNA posttranscriptional gene silencing n/ad
Piwi-interacting RNA piRNA protect genome integrity n/ae
Enhancer RNA eRNA unknown variablef
aGENCODE (Harrow et al., 2012).
bHGNC database (Seal et al., 2011; http://www.genenames.org).
c2,000–3,000 putative miRNA have been annotated (Harrow et al., 2012), but the majority are not validated.
dHuman endogenous siRNA are rare and have not been systematically identified.
ePiwi-interacting RNA (piRNA) have not been systematically identified, although estimates indicate that hundreds of piRNAs are derived from each of
more than 100 loci (Aravin et al., 2006; Brennecke et al., 2007; Girard et al., 2006).
fEnhancer RNAs (eRNAs) are generated from active enhancers, thus the number of eRNAs depends on the set of active enhancers in a cell (Kim et al.,
2010; Wang et al., 2011). Current estimates indicate that 25%–80% of active enhancers generate eRNAs.initiation occurs, can also be bound by certain transcription
factors (Dikstein, 2011; Goodrich and Tjian, 2010).
Enhancers can be identified by profiling the locations of key
transcriptional regulators genome wide and by testing whether
these DNA elements are active in enhancer-reporter vectors,
and a large population of ESC enhancers has been identified in
this manner (Chen et al., 2008). Enhancers are occupied by
nucleosomes with specific modifications and are sensitive to
DNase treatment, and these features can be used to identify
putative enhancers when the key transcriptional regulators are
not known (Buecker and Wysocka, 2012; Thurman et al.,
2012). Approximately one million putative enhancers have
recently been identified in the human genome by using, in
multiple cell types, a variety of high-throughput techniques that
detect these features of enhancers (Dunham et al., 2012;
Thurman et al., 2012). These putative enhancers provide a
resource for identifying regions of the genome where sequence
variation may impact factor binding and gene regulation and
thus contribute to disease. Recent studies suggest that a con-
siderable portion of the genetic variation that is associated with
disease occurs in these regulatory regions (Maurano et al., 2012).
Transcriptional Control of Genes
Transcriptional regulation occurs at two interconnected levels:
the first involves transcription factors and the transcription appa-
ratus, and the second involves chromatin and its regulators
(Figure 1). We briefly discuss the fundamentals of transcriptional
control in this order, noting recent advances and reviews where
the reader can obtain more detailed information.
Transcription factors can be separated into two classes based
on their regulatory responsibilities: control of initiation versus
control of elongation (Adelman and Lis, 2012; Fuda et al.,
2009; Rahl et al., 2010; Yankulov et al., 1994; Zhou et al.,
2012b). This distinction is not absolute, as some transcription1238 Cell 152, March 14, 2013 ª2013 Elsevier Inc.factors may contribute to control of both initiation and elonga-
tion. Transcription factors typically bind cofactors, which are
protein complexes that contribute to activation (coactivators)
and repression (corepressors) but do not have DNA-binding
properties of their own. Most transcription factors are thought
to contribute to transcription initiation and do so by recruiting
coactivators. These coactivators include the Mediator com-
plex, P300, and general transcription factors, among others
(Juven-Gershon and Kadonaga, 2010; Malik and Roeder, 2010;
Sikorski and Buratowski, 2009; Taatjes, 2010). Recent studies
have highlighted the importance of Mediator in integrating infor-
mation from transcriptional activators, repressors, signaling
pathways, and other regulators during transcription initiation
and during the switch to elongation (Berk, 2012; Borggrefe and
Yue, 2011; Conaway and Conaway, 2011; Kagey et al., 2010;
Kornberg, 2005; Larivie`re et al., 2012; Malik and Roeder, 2010;
Spaeth et al., 2011; Taatjes, 2010).
Once the recruited RNA polymerase II molecules initiate tran-
scription, they generally transcribe a short distance, typically
20–50 bp, and then pause (Figure 1) (Adelman and Lis, 2012).
This process is controlled by the pause control factors DSIF
and NELF, which are physically associated with the paused
RNA polymerase II molecules. The paused polymerases may
transition to active elongation through pause release, or they
may ultimately terminate transcription with release of the small
RNA species. Pause release and subsequent elongation occur
through recruitment and activation of positive transcription
elongation factor b (P-TEFb), which phosphorylates the paused
polymerase and its associated pause control factors. P-TEFb
can be brought to these sites in the form of a large complex
called the super elongation complex (SEC) (Luo et al., 2012a;
Smith et al., 2011b). Additional complexes, such as PAFc, also
contribute to the regulation of elongation (Jaehning, 2010). Tran-
scription factors such as c-Myc stimulate P-TEFb-mediated
Figure 1. Transcriptional Regulation
(A) Formation of a preinitiation complex. Transcription factors bind to specific DNA elements (enhancers) and to coactivators, which bind to RNA polymerase II,
which in turn binds to general transcription factors at the transcription start site (arrow). The DNA loop formed between the enhancer and the start site is stabilized
by cofactors such as the Mediator complex and cohesin.
(B) Initiation and pausing by RNA polymerase II. RNA polymerase II begins transcription from the initiation site, but pause control factors cause it to stall some tens
of base pairs downstream.
(C) Pause release and elongation. Various transcription factors and cofactors recruit elongation factors such as P-TEFb, which phosphorylates the pause release
factors and polymerase, allowing elongation to proceed.
(D) Chromatin structure is regulated by ATP-dependent remodeling complexes that can mobilize the nucleosome, allowing regulators and the transcription
apparatus increased access to DNA sequences.
(E) Transcriptional activity is influenced by proteins that modify and bind the histone components of nucleosomes. Some proteins add modifications (writers),
some remove modifications (erasers), and others bind via these modifications (readers). The modifications include acetylation (Ac), methylation (Me), phos-
phorylation (P), sumoylation (Su), and ubiquitination (Ub).
(F) Histone modifications occur in characteristic patterns associated with different transcriptional activities. As an example, the characteristic patterns observed
at actively transcribed genes are shown for histone H3 lysine 27 acetylation (H3K27Ac), histone H3 lysine 4 trimethylation (H3K4me3), histone H3 lysine 79
dimethylation (H3K79me2), and histone H3 lysine 36 trimethylation (H3K36me3).release of RNA polymerase II from these pause sites and thus
contribute to the control of transcription elongation (Rahl et al.,
2010).
Recent studies have provided new insights into cofactors that
play important roles in DNA loop formation and maintenance,
which are key to proper gene control. During transcription initia-
tion, the DNA loop formed between enhancers and core
promoter elements is stabilized by cohesin, which is recruited
by the NIPBL cohesin-loading protein that is associated with
Mediator (Kagey et al., 2010). The cohesin complex has circulardimensions capable of encircling two nucleosome-bound mole-
cules of DNA. Reducing the levels of cohesin or NIPBL has the
same adverse effect on transcription as reducing the levels of
Mediator, so these cofactors apparently play a similarly impor-
tant role in gene activity (Kagey et al., 2010). Although cohesin
is recruited to active promoters, it also becomes associated
with the DNA-binding factor CTCF, which has been implicated
in formation of insulator elements. Thus, cohesin is thought to
have roles in transcription activation at some genes and in
silencing at others (Dorsett, 2011; Hadjur et al., 2009; ParelhoCell 152, March 14, 2013 ª2013 Elsevier Inc. 1239
Figure 2. Master Transcriptional Regulators and Reprogramming Factors
Transcription factors that have dominant roles in the control of specific cell states and that are capable of reprogramming cell states when ectopically expressed
in various cell types (Buganim et al., 2012; Davis et al., 1987; Huang et al., 2011; Ieda et al., 2010; Kajimura et al., 2009; Marro et al., 2011; Pang et al., 2011; Sekiya
and Suzuki, 2011; Takahashi and Yamanaka, 2006; Vierbuchen et al., 2010; Xie et al., 2004; Zhou et al., 2008).et al., 2008; Phillips and Corces, 2009; Schmidt et al., 2010;
Seitan and Merkenschlager, 2012; Wendt et al., 2008).
The fundamental unit of chromatin, the nucleosome, is regu-
lated by protein complexes that can mobilize the nucleosome or
modify its histone components (Figure 1). Gene activation is
accompanied by recruitment of ATP-dependent chromatin re-
modeling complexes of the SWI/SNF family, which mobilize
nucleosomes to facilitate access of the transcription apparatus
and its regulators to DNA (Clapier and Cairns, 2009; Hargreaves
and Crabtree, 2011). In addition, there is recruitment, by tran-
scription factors and the transcription apparatus, of an array
of histone-modifying enzymes that acetylate, methylate, ubiqu-
tinylate, and otherwise chemically modify nucleosomes in
a stereotypical fashion across the span of each active gene
(Bannister and Kouzarides, 2011; Campos and Reinberg,
2009; Gardner et al., 2011; Rando, 2012; Zhu et al., 2013).
These modifications provide interaction surfaces for protein
complexes that contribute to transcriptional control. Enzymes
that remove these modifications are also typically present at
the active genes, producing a highly dynamic process of chro-
matin modification as RNA polymerase is recruited and goes
through the various steps of initiation and elongation of the
RNA species.
Repressed genes are embedded in chromatin with modifica-
tions that are characteristic of specific repression mechanisms
(Beisel and Paro, 2011; Cedar and Bergman, 2012; Jones,
2012; Moazed, 2009; Reyes-Turcu and Grewal, 2012). One
type of repressed chromatin, which contains nucleosome modi-
fications generated by the Polycomb complex (e.g., histone
H3K27me3), is found at genes that are silent but poised for acti-
vation at some later stage of development and differentiation
(Orkin and Hochedlinger, 2011; Young, 2011). Another type of
repressed chromatin is found in regions of the genome that are
fully silenced, such as that containing retrotransposons and1240 Cell 152, March 14, 2013 ª2013 Elsevier Inc.other repetitive elements (Feng et al., 2010; Lejeune and Allshire,
2011). The mechanisms that silence this latter set of genes can
involve both nucleosome modification (e.g., histone H3K9me3)
and DNA methylation.
Control of Gene Expression Programs
The set of genes that are transcribed largely defines the cell. The
gene expression program of a specific cell type includes RNA
species from genes that are active in most cells (housekeeping
genes) and genes that are active predominantly in one or a limited
number of cell types (cell-type-specific genes). In ESCs, for
example, at least 60% of the protein-coding genes are tran-
scribed into full-length mRNA species, but only a minority are
cell-type specific and thus defining for ESCs (Assou et al.,
2007). Mammals contain hundreds and possibly thousands of
cell types, and most of these have yet to be studied with respect
to the set of transcripts they contain. Thus, the terms ‘‘house-
keeping’’ and ‘‘cell-type specific’’ are relative rather than
absolute and have yet to be precisely defined. Furthermore,
the ‘‘transcriptome’’ of specific cells, derived from high-
throughput sequencing, does not show a distinct boundary
between ‘‘active’’ and ‘‘silent’’ genes, but rather shows a broad
distribution of RNA levels that ranges from less than one RNA
molecule/gene/cell to millions of RNA molecules/gene/cell, and
it is not clear what level is functionally sufficient for each RNA
species.
The particular set of transcription factors that are expressed in
any one cell type controls the selective transcription of a subset
of genes by RNA polymerase II, thereby producing the gene
expression program of the cell. Studies of the transcription
factors that are key to establishing and maintaining specific
cell states suggest that only a small number of the transcription
factors that are expressed in cells are necessary to establish cell-
type-specific gene expression programs (Figure 2). For example,
Figure 3. Features of Master Transcription Factors of ES Cells that Likely Extend to Other Cell Types
(A) Master transcription factors are expressed at high levels (30,000–300,000 molecules/cell) relative to other transcription factors.
(B) Master transcription factors dominate control of the gene expression program by forming enhancers that are associated with most active ESC genes.
(C) Master transcription factors positively regulate transcription of cell-type-specifying genes and, together with Polycomb group proteins, negatively regulate
the expression of genes that specify other cell types.
(D) Master transcription factors (circles) positively regulate their own genes (boxes), forming interconnected autoregulatory loops.althoughmore than half of the1,200 genes encoding transcrip-
tion factors show some evidence of transcription in ESCs, only
a few of these transcription factors are needed to reprogram
a broad range of cell types into induced pluripotent stem cells
(iPSCs) with features essentially indistinguishable from ESCs
(Graf, 2011; Ng and Surani, 2011; Orkin and Hochedlinger,
2011; Yamanaka, 2012; Yeo and Ng, 2013; Young, 2011). These
ESC transcription factors, which include OCT4, SOX2, and
NANOG, are expressed at high levels, bind regulatory elements
associated with most active ESC genes, are involved in
Polycomb-mediated repression of genes that specify other cell
types, and positively regulate their own gene expression through
interconnected autoregulatory loops (Figure 3) (Young, 2011).
Activation of these endogenous interconnected autoregulatory
loops may be key to cellular reprogramming by introduction of
exogenous transcription factors. Other cell types express cell-
type-specific, or lineage-specific, master transcription factorsthat are likely to share these key properties of the ESC master
transcription factors.
Most of the transcription factors that are key to control of cell
state and that can act as reprogramming factors are thought to
control transcription initiation at the genes they regulate. For
example, the ESC transcription factors OCT4 and NANOG
bind to the P300 and Mediator coactivators (Chen et al., 2008;
Kagey et al., 2010), which can then drive the formation of
open chromatin and recruitment of the transcription apparatus.
Similarly, many of the transcription factors that can reprogram
or transdifferentiate cells, including MYOD, C/EBPb, HNF1a,
HNF4a, BRN2, and GATA4, bind to at least one of these
coactivators (Borggrefe and Yue, 2011).
Recent studies have revealed that certain transcription factors
can exert a broad effect on the gene expression programs of
cells through elongation control (Figure 4). The c-Myc transcrip-
tion factor can stimulate increased elongation from essentiallyCell 152, March 14, 2013 ª2013 Elsevier Inc. 1241
Figure 4. Global Alterations in Gene Expression Programs through
Transcription Elongation
(A) Transcriptional amplification of the gene expression program. The
transcription factor c-Myc stimulates increased elongation of most actively
transcribed genes, producing increased levels of transcripts for most genes in
the gene expression program of the cell. (B) Expanded pause release extends
the gene expression program. In some cells, RNA polymerase will initiate
transcription at some genes but fails to transition to elongation. AIRE
stimulates pause release for many of these initiated genes, thus producing
transcripts for many genes that are normally expressed only in peripheral
tissues. (C) Specific pause release. Some elongation factors stimulate pause
release at specific sets of genes that are important for a particular cell’s
function.the entire active gene expression program in diverse cell types
(Lin et al., 2012; Nie et al., 2012; Rahl et al., 2010). The transcrip-
tion factor AIRE functions to expand the set of genes that
undergo RNA polymerase II pause release in specialized thymic1242 Cell 152, March 14, 2013 ª2013 Elsevier Inc.stromal cells, allowing expression of the broad spectrum of self-
antigens necessary to induce immune tolerance (Abramson
et al., 2010; Giraud et al., 2012; Oven et al., 2007; Zumer et al.,
2011). In hematopoiesis, the TIF1g transcription factor controls
erythroid cell fate by interacting with P-TEFb and regulating tran-
scription elongation at a specific set of target genes (Bai et al.,
2010). Development generally appears to be dependent on
proper elongation control; the transcription elongation factor
Tcea3 (TFIIS) contributes to the ability of ESCs to respond
appropriately to differentiation cues (Park et al., 2013), andmuta-
tions in the P-TEFb repressor HEXIM cause gross develop-
mental defects (Nguyen et al., 2012).
Summary of Recent Advances in Gene Regulation
The key themes that have emerged from recent studies in
transcriptional control and that are highlighted here are the
following. Sequence variation in enhancers plays an important
role in misregulation of gene expression and disease. A small
number of key transcription factors dominate control of gene
expression programs. Some transcription factors regulate tran-
scription initiation, whereas other factors control elongation,
and factors that control this latter step can have profound effects
on cell state. The Mediator coactivator complex integrates
signals from diverse regulators and recruits cohesin complexes
to active genes, which, in turn, contributes to both chromatin
looping and gene activity. Diverse chromatin regulators mobilize
nucleosomes and dynamically modify nucleosomes during
active gene transcription and in gene silencing, and some chro-
matin regulators are regulated by lncRNAs. These advances in
our understanding of sequences involved in gene control, tran-
scriptional circuitry, the transcription apparatus, and chromatin
regulation have led to new insights into themechanisms involved
in misregulation of gene expression in various human diseases
and disorders. We discuss some of these below.
Misregulated Gene Expression in Disease
Many diseases and syndromes are associated with mutations in
regulatory regions and in transcription factors, cofactors, chro-
matin regulators and noncoding RNAs (Table S1 available on-
line). These mutations can contribute to cancer, autoimmunity,
neurological disorders, developmental syndromes, diabetes,
cardiovascular disease, and obesity, among others. We highlight
here several insights into disease mechanisms that have
emerged from advances in our understanding of gene regulation.
Cancer
Recent studies have highlighted the link between disease-
associated variants in regulatory DNA and breast cancer (Jiang
et al., 2011), prostate cancer (Demichelis et al., 2012), colorectal
cancer (Lubbe et al., 2012), renal cancer (Schodel et al., 2012),
lung cancer (Liu et al., 2011), nasopharyngeal cancer (Yew
et al., 2012), and melanoma (Huang et al., 2013; Horn et al.,
2013). The genome instability that is a hallmark of cancer almost
certainly contributes to further alter sequences in regulatory
regions that can promote tumor progression.
Mutations in transcription factors have long been known
to contribute to tumorigenesis, and recent studies indicate
that overexpressed oncogenic transcription factors can alter
the core autoregulatory circuitry of the cell. The oncogenic
transcription factor TAL1, which is overexpressed in approxi-
mately half of the cases of T cell acute lymphoblastic leukemia
(T-ALL), forms an interconnected autoregulatory loop with
several key transcription factor partners, and this circuitry
contributes to the sustained activation of TAL1-regulated onco-
genic program (Sanda et al., 2012). Thus, high levels of TAL1
produce amodified autoregulatory circuitry that drives the onco-
genic program in T-ALL.
Most tumor cells depend on the transcription factor c-Myc for
their growth and proliferation (Littlewood et al., 2012).MYC is the
most frequently amplified oncogene, and the elevated expres-
sion of its gene product is associated with tumor aggression
and poor clinical outcome. Elevated levels of c-Myc can promote
tumorigenesis in a wide range of tissues. In tumor cells express-
ing high levels of c-Myc, the transcription factor accumulates in
the promoter regions of most active genes, recruits the tran-
scription elongation factor P-TEFb, and causes transcriptional
amplification, producing increased levels of transcripts within
the cell’s gene expression program (Lin et al., 2012; Nie et al.,
2012). Thus, rather than binding and regulating a new set of
genes when overexpressed, c-Myc amplifies the output of the
existing gene expression program (Figure 4). These results
suggest that transcriptional amplification reduces rate-limiting
constraints for tumor cell growth and proliferation.
Mutations in the Mediator coactivator complex have recently
been implicated in the development of various tumors. Uterine
leiomyomas, or fibroids, are benign tumors that affect millions
of women. The MED12 gene is altered in the majority of uterine
leiomyomas, and its expression is absent in many uterine
leiomyosarcomas, the malignant counterparts of leiomyomas
(Ma¨kinen et al., 2011a, 2011b). MED12 mutations also occur
frequently in prostate cancer (Barbieri et al., 2012). MED12 is
part of the CDK module of the Mediator complex, and the
CDK8 subunit of this module has been reported to act as an
oncogene in both colon cancer and melanoma (Firestein et al.,
2008; Kapoor et al., 2010; Morris et al., 2008). Mediator has roles
in gene activation and repression and can function both in
transcription initiation and elongation, so further study is needed
to establish howMediator mutations contribute to these tumors.
Mediator-associated NIPBL recruits cohesin. Alterations in co-
hesin expression and function have been noted in some cancer
cells, and there is speculation that cohesin misregulation may
also contribute to development of various cancers, but direct
evidence for a role of cohesin in cancer remains to be estab-
lished (Mannini and Musio, 2011; Xu et al., 2011).
Mutations in a variety of chromatin regulators have been
implicated in development of cancer cells, and the normal func-
tions of these regulators provide some clues to the mechanisms
involved in altered gene expression. Loss-of-function mutations
in several nucleosome remodeling proteins, including ARID1A,
SMARCA4 (BRG1), and SMARCB1 (INI1), are associated with
multiple types of cancer (Dawson and Kouzarides, 2012;
Hargreaves and Crabtree, 2011; Tsai and Baylin, 2011; Wilson
and Roberts, 2011), suggesting that defects in mobilizing nucle-
osomes near the promoters of active genes are involved. Simi-
larly, various mutations in the Polycomb components EZH2
and SUZ12 and in the DNA methylation apparatus occur in
multiple cancers, suggesting that, in these instances, it is theloss of proper gene silencing that contributes to tumorigenesis
(Cedar and Bergman, 2012; Jones, 2012; Margueron and
Reinberg, 2011; Mills, 2010). The majority of malignant mela-
nomas overexpress SETDB1, a histone H3K9 methyltransferase
that can contribute to gene activation or silencing, and this
causes deregulation of HOX genes and accelerates melanoma
(Ceol et al., 2011).
Gene fusions with the chromatin regulator MLL in leukemias
are now known to alter transcription elongation (Luo et al.,
2012b; Marschalek, 2010; Slany, 2009; Smith et al., 2011a).
Several translocation partners of MLL are components of
a SEC that includes P-TEFb and ELL proteins, which have also
been shown to control transcription elongation (Lin et al., 2010,
2011; Luo et al., 2012a; Smith et al., 2011b). It is thought that
translocation of any of the SEC subunits to the amino-terminal
domain of MLL abnormally stabilizes the localization of the
SEC at MLL target genes, including HOXA9 and HOXA10, which
leads to excessive stimulation of RNA polymerase II into produc-
tive elongation at these genomic loci, which in turn contributes to
aggressive acute leukemia.
Specific lncRNAs have recently been implicated in cancer
progression. The ANRIL lncRNAmediates transcriptional repres-
sion of members of the INK4A/ARF/INK4B locus, which encode
tumor suppressors whose repression is associated with various
cancers (Aguilo et al., 2011; Popov and Gil, 2010). ANRIL func-
tions by recruiting polycomb repressive complexes 1 and 2
(PRC1 and PRC2), and misregulation of ANRIL may lead to
abnormal silencing of tumor suppressors and thus contribute
to cancer progression (Kotake et al., 2011; Yap et al., 2010).
Interestingly, genome-wide association studies have identified
numerous polymorphisms that affect the expression and pro-
cessing of ANRIL and are associated with increased suscepti-
bility to an increasing variety of disease states, including multiple
types of cancer, coronary artery disease, and type 2 diabetes
(Pasmant et al., 2011; Harismendy et al., 2011).
Autoimmunity and Inflammation
Mutations in the autoimmune regulator (AIRE) protein cause type
I autoimmune polyendocrinopathy syndrome. AIRE is a tran-
scription factor whose role in promoting transcriptional elonga-
tion at genes with paused RNA polymerase II in the thymus
explains why loss of AIRE function leads to autoimmune disease.
Self-reactive T cells are normally eliminated during maturation in
the thymus due to the specialized ability of thymic stromal cells
and, in particular, medullary epithelial cells (MECs) to transcribe
a large repertoire of genes encoding peripheral tissue antigens
(Kyewski and Klein, 2006). This ectopic gene expression is
controlled in a large part by AIRE, which is expressed almost
exclusively in MECs. Mice and humans with an AIRE gene defect
express only a fraction of the peripheral tissue antigens and
develop immune infiltrates and autoantibodies directed at
multiple peripheral tissues (Akirav et al., 2011; Gardner et al.,
2009; Mathis and Benoist, 2009; Metzger and Anderson,
2011). Recent studies have shown that AIRE interacts with
P-TEFb and influences transcription elongation in primary
MECs (Abramson et al., 2010; Giraud et al., 2012; Oven et al.,
2007; Zumer et al., 2011). AIRE is physically associated with all
the active genes in MECs but has its greatest effect on genes
that do not experience pause release in its absence (Figure 4).Cell 152, March 14, 2013 ª2013 Elsevier Inc. 1243
These results are consistent with the idea that AIRE causes the
release of RNA polymerase II molecules that are nonproductively
paused at the promoters of a broad spectrum of genes that are
otherwise expressed only in peripheral tissues. Thus, in MECs,
AIRE’s function is to expand the set of genes that undergoes
RNA polymerase II pause release.
Misregulation of the immune response transcriptional regu-
lator NF-kB has been linked to inflammatory and autoimmune
diseases, improper immune development, and cancer. NF-kB
is found in most cell types and is involved in cellular responses
to stimuli such as infection and stress (Hayden and Ghosh,
2012). The transcription factor controls genes involved in inflam-
mation and is chronically active in inflammatory diseases such as
inflammatory bowel disease, arthritis, sepsis, gastritis, asthma,
and atherosclerosis. Although most research into the mecha-
nism of transcriptional activation by this and other regulators
has focused on coactivator recruitment, evidence that NF-kB
interacts with BRD4 and P-TEFb suggests that this ubiquitous
regulator plays a role in elongation control at inflammatory genes
during immune and stress responses (Barboric et al., 2001;
Huang et al., 2009; Nowak et al., 2008). This view is supported
by evidence that inhibitors of BRD4, which contributes to recruit-
ing active P-TEFb, suppress expression of key inflammatory
genes in activated macrophages and confer protection against
lipopolysaccharide-induced endotoxic shock and bacteria-
induced sepsis (Nicodeme et al., 2010).
Developmental Disorders: Neurological
Mutations in various components of the Mediator coactivator
have been linked to a variety of neurological disorders and other
developmental deficiencies (Ding et al., 2008; Goh and Grants,
2012; Hashimoto et al., 2011; Kaufmann et al., 2010; Leal
et al., 2009; Philibert et al., 2007; Risheg et al., 2007; Rump
et al., 2011; Schwartz et al., 2007; Zhou et al., 2012a). Mutations
in MED23 alter the interaction between enhancer-bound tran-
scription factors and Mediator, leading to transcriptional dysre-
gulation of mitogen-responsive immediate-early genes that
affect brain development and plasticity. A similar defect in imme-
diate-early gene expression is observed in cells from patients
with another intellectual disability, Opitz-Kaveggia syndrome,
which is caused byMED12mutations. It would not be surprising
to find that additional Mediator mutations contribute to neurolog-
ical disorders, given the role of this coactivator in integrating
information from transcriptional activators, repressors, and
signaling pathways.
Heterozygous germline mutations in components of the SWI/
SNF chromatin remodeling complex were recently identified in
patients with various neurological syndromes whose common
features are severe intellectual disability and speech delay
(Hoyer et al., 2012; Santen et al., 2012a, 2012b; Tsurusaki
et al., 2012; Van Houdt et al., 2012). These mutations were found
in SMARCB1, SMARCA4, SMARCA2, SMARCE1, ARID1A, and
ARID1B. It has been suggested that up to 3% of unexplained
intellectual disability may be caused by mutations in genes
encoding SWI/SNF components (Santen et al., 2012b). It is inter-
esting to note that ARID1B component of human SWI/SNF
interacts with elongin C (Li et al., 2010), a component of the
SIII transcription elongation factor, which enhances transcrip-
tion elongation by suppressing transient pausing of RNA1244 Cell 152, March 14, 2013 ª2013 Elsevier Inc.polymerase II (Aso et al., 1995). Thus, alterations in SWI/SNF
complexes have the potential to affect both chromatin remodel-
ing and transcription elongation.
Developmental Disorders: Cohesinopathies
Cohesinopathies are characterized by a wide variety of develop-
mental defects, including growth and mental retardation, limb
deformities, and craniofacial anomalies (Bose and Gerton,
2010; Liu and Krantz, 2008). This broad spectrum of phenotypes
is now thought to be due to reduced cohesin loading and cohesin
function in gene expression during development. A variety of
cohesinopathies have been described, including Cornelia de
Lange syndrome and Roberts syndrome, in which patients
have mutations in the cohesin loading protein NIPBL or the
proteins that constitute the cohesin complex. With recent
evidence for roles of cohesin complexes in regulation of gene
expression and DNA looping (Kagey et al., 2010; Kawauchi
et al., 2009; Liu et al., 2009; Schaaf et al., 2009; Seitan et al.,
2011), it has become apparent that these deficiencies lead to
defects in transcriptional regulation and probably to the overall
structure of chromatin in the nucleus of disease cells.
Diabetes
Diabetes mellitus is a group of metabolic diseases in which
a person has elevated blood sugar either because the pancreas
fails to produce adequate amounts of insulin or because cells do
not respond properly to the insulin that is produced. Mutations in
pancreatic master transcription factors and the sequences they
bind have been implicated in diabetes. The gene expression
programs of pancreatic cells appear to be controlled by a small
set of key transcription factors, including HNF1a, HNF1b,
HNF4a, PDX1, and NEUROD1, some of which contribute to
the interconnected autoregulatory circuitry of these cells
(Odom et al., 2004). Mutations in any of these factors can result
in various forms of maturity-onset diabetes of the young (MODY)
(Maestro et al., 2007; Malecki, 2005). These mutations almost
certainly have a deleterious effect on the interconnected autore-
gulatory circuitry formed by these factors and their target genes.
The frequency of SNPs that are linked to defects in glucose
homeostasis and diabetes is greatly enriched in the binding sites
for these transcription factors (Maurano et al., 2012). This obser-
vation indicates that perturbations that affect the regulatory
circuitry of pancreatic cells may contribute to diabetes. It also
suggests that previously undiscovered regulatory networks
and network architectures may be uncovered by incorporating
information about disease-associated genetic variants and
knowledge of the binding sites of diverse transcription factors.
Cardiovascular Disease
Misregulated development of the cardiovascular system is
among the most common class of congenital birth defects,
and diseases of the cardiovascular system are among the
most prevalent clinical issues for adult populations (Bruneau,
2008; Kathiresan and Srivastava, 2012; Roger et al., 2012). It is
well established that loss-of-function mutations in certain tran-
scription factors cause various cardiovascular deficiencies
(Table S1), but new studies have highlighted the role that muta-
tions in ncRNA species can play in cardiovascular diseases.
Specific miRNAs have been implicated in both the promo-
tion and inhibition of differentiation into cardiac lineages,
cardiac hypertrophy, vascular differentiation, and erythropoiesis
(Han et al., 2011; Papageorgiou et al., 2012; Small and Olson,
2011). MicroRNAs have also been linked to causative and
protective roles for multiple types of cardiovascular disease,
including arrhythmia, fibrosis, hypertrophy due to high pressure,
and misregulation of cardiac energy metabolism (Callis et al.,
2009; Care` et al., 2007; Grueter et al., 2012; Thum et al., 2008;
van Rooij et al., 2007, 2008; Yang et al., 2007). MicroRNAs are
thought to fine-tune gene expression, and thus, the alterations
in these cases are thought to lead to deficiencies in fine-tuning
the cardiovascular gene expression program.
Summary and Outlook
Several concepts have emerged from recent studies of gene
expression programs in healthy and in diseased cells. Genetic
variationmay contribute to disease largely throughmisregulation
of gene expression. Mutations in the transcription factors that
control cell state may impact the autoregulatory loops that are
at the core of cellular regulatory circuitry, leading to the loss of
a normal healthy cell state. Some transcription factors control
RNA polymerase II pause release and elongation and, when their
expression or function is altered, can produce aggressive tumor
cells (c-Myc) or some forms of autoimmunity (AIRE). Mutations in
the coactivator complexes that integrate information from many
transcription factors and contribute to DNA looping can cause
a broad spectrum of developmental diseases. Alterations in
specific chromatin regulators can contribute to development of
cancer and many other diseases. Misregulation of noncoding
RNAs can also contribute to disease. Additional insights into
the role of transcriptional misregulation in human disease will
require improved genome annotation, knowledge of the DNA
sequences whose alterations contribute to disease, identifica-
tion of the key transcriptional regulators of all cells of medical
relevance, and further understanding of the roles of cofactors,
chromatin regulators, and ncRNAs.
It is essential to improve human genome annotation in order to
more fully understand gene expression programs and their regu-
lation and, thus, gene misregulation in disease. As a first step, it
would be ideal to identify the complete set of protein-coding and
noncoding genes and to ascertain which of these are actively
transcribed in specific cell types. There are considerable chal-
lenges associated with defining the complete set of expressed
genes in any one type of mammalian cell. Such characterization
has traditionally required large numbers of cells, and for most
primary cell types, it is challenging to obtain a homogeneous
population of cells. Whereas protein-coding genes can be
recognized, at least in part, by the presence of a coding
sequence, it is challenging to produce a complete and accurate
annotation of ncRNA genes due to limitations in the read length
of widely used sequence technologies and the short lifetime of
many ncRNAs. Nonetheless, recent studies have identified
a vast number and variety of ncRNAs in human cells, so there
is promise that improved human genome annotation is at hand
(Djebali et al., 2012). Furthermore, new technologies allow inves-
tigators tomonitor RNA polymerase II molecules that are actively
engaged in transcription (Core et al., 2008). Such approaches
have recently provided evidence that most lncRNA species are
the product of divergent transcription from the promoters of
active protein coding genes (Sigova et al., 2013). This suggeststhat most active protein-coding genes in humans are actually
divergently transcribed mRNA/lncRNA gene pairs.
Knowledge of the sequence variation that contributes to
disease is being gained at a rapid pace, and this will improve
our understanding of disease mechanisms and lead to new
approaches to disease diagnosis and therapy. Several lines of
evidence suggest that much of genetic variation contributes to
disease through misregulation of gene expression. A substantial
portion of the genomic sequences that are under positive selec-
tion are thought to be regulatory (Grossman et al., 2010).
Disease-associated SNPs are enriched in regulatory regions
(Ernst et al., 2011; Hindorff et al., 2009; Maurano et al., 2012).
Many recent studies have identified links between disease-asso-
ciated variants in regulatory DNA and a broad spectrum of
human diseases, including cancer (Demichelis et al., 2012;
Huang et al., 2013; Horn et al., 2013; Jiang et al., 2011; Liu
et al., 2011; Lubbe et al., 2012; Schodel et al., 2012; Yew
et al., 2012), congenital heart disease (Zhao et al., 2012), inflam-
matory lung disease (Han et al., 2012), multiple sclerosis (Alcina
et al., 2013), Alzheimer’s disease (Gaj et al., 2012), abdominal
aortic aneurysm (Bown et al., 2011), amyotrophic lateral scle-
rosis (Iida et al., 2011), and coronary artery disease (Harismendy
et al., 2011). Disease-associated genetic variants in regulatory
regions are most often found in regions that are utilized in
a cell-type-specific manner and are associated with diseases
of the corresponding cell type (Ernst et al., 2011; Maurano
et al., 2012). Thus, cell-type-specific enhancer use can explain
how genetic variants produce tissue-specific diseases.
Disease-associated genetic variants can exist in regulatory
regions that are very distant from the genes they control, but
knowledge of the nature of loops between such distal enhancers
and their target genes can explain how these distant variants
affect a specific gene and its biological functions (Li et al.,
2012; Maurano et al., 2012).
Genetic investigations and reprogramming studies suggest
that only a small number of the hundreds of transcription factors
that are expressed in cells are essential for establishing and
maintaining the regulatory networks that produce specific cell
states. If this holds true for most cell types, then it would be ideal
to identify the key transcription factors for all cell types of
medical relevance. It should be possible to identify these tran-
scription factors if they have features identified for their counter-
parts in well-studied cells: relative high expression, occupancy
of enhancers associated with a large fraction of active genes,
and formation of interconnected autoregulatory loops. Discov-
ering how gene expression programs are controlled in many
different cell types should lead to further understanding of regu-
latory circuitry, facilitate cellular reprogramming, and accelerate
the new field of regenerative medicine.
Cofactors and chromatin regulators are generally expressed in
most cell types, but mutations in these genes often produce
diseases or syndromes that exhibit tissue-specific disease
phenotypes (Table S1). For example, defects in Mediator
subunits contribute to nonsyndromic intellectual disability,
Charcot-Marie-Tooth disease, Opitz-Kaveggia and Lujan
syndromes, and infantile cerebral and cerebellar atrophy and
have been implicated in prostate cancer, deficiencies in
systemic energy homeostasis (Grueter et al., 2012), and alteredCell 152, March 14, 2013 ª2013 Elsevier Inc. 1245
hair-cycling (Nakajima et al., 2013; Oda et al., 2012). Improved
understanding of the interactions between cofactors and tran-
scription factors and the mechanisms involved in information
integration by these complex apparatuses will be valuable for
understanding the mechanisms that produce tissue-specific
phenotypes. Similarly, it will be important to further understand
the collaboration between the transcription apparatus and chro-
matin regulators in global control of gene expression programs.
Recent efforts to target chromatin regulators for cancer therapy
(Dawson et al., 2012) would benefit from a fuller understanding of
the regulatory mechanisms and pathways that are impacted by
these potential therapeutics.
Our future understanding of disease and the advance of
personalized medicine will benefit from models of human tran-
scriptional regulatory circuitry that integrate information about
regulatory sequences and the key transcription factors, cofac-
tors, chromatin regulators, and ncRNAs that operate at regula-
tory sites. The development of these models should thus be
among the priorities of biomedical research.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one table and can be found with this article
online at http://dx.doi.org/10.1016/j.cell.2013.02.014.
ACKNOWLEDGMENTS
Our description of the themes highlighted in this review benefited from
discussions with Karen Adelman, Jay Bradner, Gerald Crabtree, Rudolf
Jaenisch, Ian Krantz, Lee Lawton, David Levens, John Lis, Alex Marson,
Matthias Merkenschlager, Alan Mullen, Duncan Odom, David Price, Peter
Rahl, Robert Roeder, Ali Shilatifard, Phil Sharp, Alla Sigova, Alexander Stark,
Dylan Taatjes, Robert Weinberg, and Leonard Zon. We thank David Orlando
for help with data collation and analysis. This work was supported by National
Institutes of Health grants HG002668 (R.A.Y.) and CA146445 (R.A.Y.
and T.I.L.).
REFERENCES
Abramson, J., Giraud, M., Benoist, C., and Mathis, D. (2010). Aire’s partners in
the molecular control of immunological tolerance. Cell 140, 123–135.
Adelman, K., and Lis, J.T. (2012). Promoter-proximal pausing of RNA
polymerase II: emerging roles in metazoans. Nat. Rev. Genet. 13, 720–731.
Aguilo, F., Zhou, M.M., and Walsh, M.J. (2011). Long noncoding RNA,
polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. Cancer
Res. 71, 5365–5369.
Akirav, E.M., Ruddle, N.H., and Herold, K.C. (2011). The role of AIRE in human
autoimmune disease. Nat. Rev. Endocrinol. 7, 25–33.
Alcina, A., Fedetz, M., Ferna´ndez, O., Saiz, A., Izquierdo, G., Lucas, M., Leyva,
L., Garcı´a-Leo´n, J.A., Abad-Grau, Mdel.M., Alloza, I., et al. (2013). Identifica-
tion of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus
associated with multiple sclerosis. J. Med. Genet. 50, 25–33.
Aravin, A., Gaidatzis, D., Pfeffer, S., Lagos-Quintana, M., Landgraf, P., Iovino,
N., Morris, P., Brownstein, M.J., Kuramochi-Miyagawa, S., Nakano, T., et al.
(2006). A novel class of small RNAs bind to MILI protein in mouse testes.
Nature 442, 203–207.
Aso, T., Lane, W.S., Conaway, J.W., and Conaway, R.C. (1995). Elongin (SIII):
a multisubunit regulator of elongation by RNA polymerase II. Science 269,
1439–1443.
Assou, S., Le Carrour, T., Tondeur, S., Stro¨m, S., Gabelle, A., Marty, S., Nadal,
L., Pantesco, V., Re´me, T., Hugnot, J.P., et al. (2007). A meta-analysis of1246 Cell 152, March 14, 2013 ª2013 Elsevier Inc.human embryonic stem cells transcriptome integrated into a web-based
expression atlas. Stem Cells 25, 961–973.
Bai, X., Kim, J., Yang, Z., Jurynec, M.J., Akie, T.E., Lee, J., LeBlanc, J., Sessa,
A., Jiang, H., DiBiase, A., et al. (2010). TIF1gamma controls erythroid cell fate
by regulating transcription elongation. Cell 142, 133–143.
Bannister, A.J., and Kouzarides, T. (2011). Regulation of chromatin by histone
modifications. Cell Res. 21, 381–395.
Barbieri, C.E., Baca, S.C., Lawrence, M.S., Demichelis, F., Blattner, M.,
Theurillat, J.P., White, T.A., Stojanov, P., Van Allen, E., Stransky, N., et al.
(2012). Exome sequencing identifies recurrent SPOP, FOXA1 and MED12
mutations in prostate cancer. Nat. Genet. 44, 685–689.
Barboric, M., Nissen, R.M., Kanazawa, S., Jabrane-Ferrat, N., and Peterlin,
B.M. (2001). NF-kappaB binds P-TEFb to stimulate transcriptional elongation
by RNA polymerase II. Mol. Cell 8, 327–337.
Bartel, D.P. (2009). MicroRNAs: target recognition and regulatory functions.
Cell 136, 215–233.
Beisel, C., and Paro, R. (2011). Silencing chromatin: comparing modes and
mechanisms. Nat. Rev. Genet. 12, 123–135.
Berk, A.J. (2012). Yin and yang of mediator function revealed by human
mutants. Proc. Natl. Acad. Sci. USA 109, 19519–19520.
Bonasio, R., Tu, S., and Reinberg, D. (2010). Molecular signals of epigenetic
states. Science 330, 612–616.
Borggrefe, T., and Yue, X. (2011). Interactions between subunits of the
Mediator complex with gene-specific transcription factors. Semin. Cell Dev.
Biol. 22, 759–768.
Bose, T., and Gerton, J.L. (2010). Cohesinopathies, gene expression, and
chromatin organization. J. Cell Biol. 189, 201–210.
Bown, M.J., Jones, G.T., Harrison, S.C., Wright, B.J., Bumpstead, S., Baas,
A.F., Gretarsdottir, S., Badger, S.A., Bradley, D.T., Burnand, K., et al.;
CARDIoGRAM Consortium; Global BPgen Consortium; DIAGRAM Consor-
tium; VRCNZ Consortium. (2011). Abdominal aortic aneurysm is associated
with a variant in low-density lipoprotein receptor-related protein 1. Am. J.
Hum. Genet. 89, 619–627.
Brennecke, J., Aravin, A.A., Stark, A., Dus, M., Kellis, M., Sachidanandam, R.,
and Hannon, G.J. (2007). Discrete small RNA-generating loci as master regu-
lators of transposon activity in Drosophila. Cell 128, 1089–1103.
Bruneau, B.G. (2008). The developmental genetics of congenital heart disease.
Nature 451, 943–948.
Buecker, C., and Wysocka, J. (2012). Enhancers as information integration
hubs in development: lessons from genomics. Trends Genet. 28, 276–284.
Buganim, Y., Itskovich, E., Hu, Y.C., Cheng, A.W., Ganz, K., Sarkar, S., Fu, D.,
Welstead, G.G., Page, D.C., and Jaenisch, R. (2012). Direct reprogramming of
fibroblasts into embryonic Sertoli-like cells by defined factors. Cell Stem Cell
11, 373–386.
Callis, T.E., Pandya, K., Seok, H.Y., Tang, R.H., Tatsuguchi, M., Huang, Z.P.,
Chen, J.F., Deng, Z., Gunn, B., Shumate, J., et al. (2009). MicroRNA-208a is
a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest.
119, 2772–2786.
Campos, E.I., and Reinberg, D. (2009). Histones: annotating chromatin. Annu.
Rev. Genet. 43, 559–599.
Care`, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang,
M.L., Segnalini, P., Gu, Y., Dalton, N.D., et al. (2007). MicroRNA-133 controls
cardiac hypertrophy. Nat. Med. 13, 613–618.
Cedar, H., and Bergman, Y. (2012). Programming of DNAmethylation patterns.
Annu. Rev. Biochem. 81, 97–117.
Ceol, C.J., Houvras, Y., Jane-Valbuena, J., Bilodeau, S., Orlando, D.A.,
Battisti, V., Fritsch, L., Lin, W.M., Hollmann, T.J., Ferre´, F., et al. (2011). The
histone methyltransferase SETDB1 is recurrently amplified in melanoma and
accelerates its onset. Nature 471, 513–517.
Chen, X., Xu, H., Yuan, P., Fang, F., Huss,M., Vega, V.B.,Wong, E., Orlov, Y.L.,
Zhang, W., Jiang, J., et al. (2008). Integration of external signaling pathways
with the core transcriptional network in embryonic stem cells. Cell 133, 1106–
1117.
Clapier, C.R., and Cairns, B.R. (2009). The biology of chromatin remodeling
complexes. Annu. Rev. Biochem. 78, 273–304.
Conaway, R.C., and Conaway, J.W. (2011). Function and regulation of the
Mediator complex. Curr. Opin. Genet. Dev. 21, 225–230.
Core, L.J., Waterfall, J.J., and Lis, J.T. (2008). Nascent RNA sequencing
reveals widespread pausing and divergent initiation at human promoters.
Science 322, 1845–1848.
Davis, R.L., Weintraub, H., and Lassar, A.B. (1987). Expression of a single
transfected cDNA converts fibroblasts to myoblasts. Cell 51, 987–1000.
Dawson, M.A., and Kouzarides, T. (2012). Cancer epigenetics: from mecha-
nism to therapy. Cell 150, 12–27.
Dawson, M.A., Kouzarides, T., and Huntly, B.J. (2012). Targeting epigenetic
readers in cancer. N. Engl. J. Med. 367, 647–657.
Demichelis, F., Setlur, S.R., Banerjee, S., Chakravarty, D., Chen, J.Y., Chen,
C.X., Huang, J., Beltran, H., Oldridge, D.A., Kitabayashi, N., et al. (2012).
Identification of functionally active, low frequency copy number variants at
15q21.3 and 12q21.31 associated with prostate cancer risk. Proc. Natl.
Acad. Sci. USA 109, 6686–6691.
Dikstein, R. (2011). The unexpected traits associated with core promoter
elements. Transcription 2, 201–206.
Ding, N., Zhou, H., Esteve, P.O., Chin, H.G., Kim, S., Xu, X., Joseph, S.M.,
Friez, M.J., Schwartz, C.E., Pradhan, S., and Boyer, T.G. (2008). Mediator links
epigenetic silencing of neuronal gene expression with x-linked mental retarda-
tion. Mol. Cell 31, 347–359.
Djebali, S., Davis, C.A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A.,
Tanzer, A., Lagarde, J., Lin, W., Schlesinger, F., et al. (2012). Landscape of
transcription in human cells. Nature 489, 101–108.
Dorsett, D. (2011). Cohesin: genomic insights into controlling gene transcrip-
tion and development. Curr. Opin. Genet. Dev. 21, 199–206.
Dunham, I., Kundaje, A., Aldred, S.F., Collins, P.J., Davis, C.A., Doyle, F.,
Epstein, C.B., Frietze, S., Harrow, J., Kaul, R., et al.; ENCODE Project Consor-
tium. (2012). An integrated encyclopedia of DNA elements in the human
genome. Nature 489, 57–74.
Ebert, M.S., and Sharp, P.A. (2012). Roles for microRNAs in conferring robust-
ness to biological processes. Cell 149, 515–524.
Ernst, J., Kheradpour, P., Mikkelsen, T.S., Shoresh, N., Ward, L.D., Epstein,
C.B., Zhang, X., Wang, L., Issner, R., Coyne, M., et al. (2011). Mapping and
analysis of chromatin state dynamics in nine human cell types. Nature 473,
43–49.
Feng, S., Jacobsen, S.E., and Reik, W. (2010). Epigenetic reprogramming in
plant and animal development. Science 330, 622–627.
Firestein, R., Bass, A.J., Kim, S.Y., Dunn, I.F., Silver, S.J., Guney, I., Freed, E.,
Ligon, A.H., Vena, N., Ogino, S., et al. (2008). CDK8 is a colorectal cancer
oncogene that regulates beta-catenin activity. Nature 455, 547–551.
Fuda, N.J., Ardehali, M.B., and Lis, J.T. (2009). Defining mechanisms that
regulate RNA polymerase II transcription in vivo. Nature 461, 186–192.
Gaj, P., Paziewska, A., Bik, W., Da˛browska, M., Baranowska-Bik, A.,
Styczynska, M., Chodakowska- _Zebrowska, M., Pfeffer-Baczuk, A.,
Barcikowska, M., Baranowska, B., and Ostrowski, J. (2012). Identification of
a late onset Alzheimer’s disease candidate risk variant at 9q21.33 in Polish
patients. J. Alzheimers Dis. 32, 157–168.
Gardner, J.M., Fletcher, A.L., Anderson, M.S., and Turley, S.J. (2009). AIRE in
the thymus and beyond. Curr. Opin. Immunol. 21, 582–589.
Gardner, K.E., Allis, C.D., and Strahl, B.D. (2011). Operating on chromatin,
a colorful language where context matters. J. Mol. Biol. 409, 36–46.
Girard, A., Sachidanandam, R., Hannon, G.J., and Carmell, M.A. (2006). A
germline-specific class of small RNAs binds mammalian Piwi proteins. Nature
442, 199–202.
Giraud, M., Yoshida, H., Abramson, J., Rahl, P.B., Young, R.A., Mathis, D., and
Benoist, C. (2012). Aire unleashes stalled RNA polymerase to induce ectopicgene expression in thymic epithelial cells. Proc. Natl. Acad. Sci. USA 109,
535–540.
Goh, Y.S., and Grants, J.M. (2012). Mutations in the Mediator subunit
MED23 link intellectual disability to immediate early gene regulation. Clin.
Genet. 81, 430.
Goodrich, J.A., and Tjian, R. (2010). Unexpected roles for core promoter
recognition factors in cell-type-specific transcription and gene regulation.
Nat. Rev. Genet. 11, 549–558.
Graf, T. (2011). Historical origins of transdifferentiation and reprogramming.
Cell Stem Cell 9, 504–516.
Grossman, S.R., Shlyakhter, I., Karlsson, E.K., Byrne, E.H., Morales, S.,
Frieden, G., Hostetter, E., Angelino, E., Garber, M., Zuk, O., et al. (2010). A
composite of multiple signals distinguishes causal variants in regions of posi-
tive selection. Science 327, 883–886.
Grueter, C.E., van Rooij, E., Johnson, B.A., DeLeon, S.M., Sutherland, L.B., Qi,
X., Gautron, L., Elmquist, J.K., Bassel-Duby, R., and Olson, E.N. (2012). A
cardiac microRNA governs systemic energy homeostasis by regulation of
MED13. Cell 149, 671–683.
Hadjur, S., Williams, L.M., Ryan, N.K., Cobb, B.S., Sexton, T., Fraser, P.,
Fisher, A.G., and Merkenschlager, M. (2009). Cohesins form chromosomal
cis-interactions at the developmentally regulated IFNG locus. Nature 460,
410–413.
Han, M., Toli, J., and Abdellatif, M. (2011). MicroRNAs in the cardiovascular
system. Curr. Opin. Cardiol. 26, 181–189.
Han, Y.J., Ma, S.F., Wade, M.S., Flores, C., and Garcia, J.G. (2012). An intronic
MYLK variant associated with inflammatory lung disease regulates promoter
activity of the smooth muscle myosin light chain kinase isoform. J. Mol.
Med. 90, 299–308.
Hargreaves, D.C., and Crabtree, G.R. (2011). ATP-dependent chromatin
remodeling: genetics, genomics and mechanisms. Cell Res. 21, 396–420.
Harismendy, O., Notani, D., Song, X., Rahim, N.G., Tanasa, B., Heintzman, N.,
Ren, B., Fu, X.D., Topol, E.J., Rosenfeld, M.G., and Frazer, K.A. (2011). 9p21
DNA variants associated with coronary artery disease impair interferon-g sig-
nalling response. Nature 470, 264–268.
Harrow, J., Frankish, A., Gonzalez, J.M., Tapanari, E., Diekhans, M.,
Kokocinski, F., Aken, B.L., Barrell, D., Zadissa, A., Searle, S., et al. (2012).
GENCODE: the reference human genome annotation for The ENCODE
Project. Genome Res. 22, 1760–1774.
Hashimoto, S., Boissel, S., Zarhrate, M., Rio, M., Munnich, A., Egly, J.M., and
Colleaux, L. (2011). MED23 mutation links intellectual disability to dysregula-
tion of immediate early gene expression. Science 333, 1161–1163.
Hayden, M.S., and Ghosh, S. (2012). NF-kB, the first quarter-century: remark-
able progress and outstanding questions. Genes Dev. 26, 203–234.
Hindorff, L.A., Sethupathy, P., Junkins, H.A., Ramos, E.M., Mehta, J.P.,
Collins, F.S., and Manolio, T.A. (2009). Potential etiologic and functional impli-
cations of genome-wide association loci for human diseases and traits. Proc.
Natl. Acad. Sci. USA 106, 9362–9367.
Ho, L., and Crabtree, G.R. (2010). Chromatin remodelling during development.
Nature 463, 474–484.
Horn, S., Figl, A., Rachakonda, P.S., Fischer, C., Sucker, A., Gast, A., Kadel,
S., Moll, I., Nagore, E., Hemminki, K., et al. (2013). TERT promoter mutations
in familial and sporadic melanoma. Science 339, 959–961.
Hoyer, J., Ekici, A.B., Endele, S., Popp, B., Zweier, C., Wiesener, A.,
Wohlleber, E., Dufke, A., Rossier, E., Petsch, C., et al. (2012). Haploinsuffi-
ciency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling
complex, is a frequent cause of intellectual disability. Am. J. Hum. Genet.
90, 565–572.
Huang, B., Yang, X.D., Zhou, M.M., Ozato, K., and Chen, L.F. (2009). Brd4
coactivates transcriptional activation of NF-kappaB via specific binding to
acetylated RelA. Mol. Cell. Biol. 29, 1375–1387.
Huang, P., He, Z., Ji, S., Sun, H., Xiang, D., Liu, C., Hu, Y., Wang, X., and Hui, L.
(2011). Induction of functional hepatocyte-like cells from mouse fibroblasts by
defined factors. Nature 475, 386–389.Cell 152, March 14, 2013 ª2013 Elsevier Inc. 1247
Huang, F.W., Hodis, E., Xu, M.J., Kryukov, G.V., Chin, L., and Garraway, L.A.
(2013). Highly recurrent TERT promoter mutations in human melanoma.
Science 339, 957–959.
Ieda, M., Fu, J.D., Delgado-Olguin, P., Vedantham, V., Hayashi, Y., Bruneau,
B.G., and Srivastava, D. (2010). Direct reprogramming of fibroblasts into func-
tional cardiomyocytes by defined factors. Cell 142, 375–386.
Iida, A., Takahashi, A., Kubo, M., Saito, S., Hosono, N., Ohnishi, Y., Kiyotani,
K., Mushiroda, T., Nakajima, M., Ozaki, K., et al. (2011). A functional variant
in ZNF512B is associated with susceptibility to amyotrophic lateral sclerosis
in Japanese. Hum. Mol. Genet. 20, 3684–3692.
Jacob, F., and Monod, J. (1961). Genetic regulatory mechanisms in the
synthesis of proteins. J. Mol. Biol. 3, 318–356.
Jaehning, J.A. (2010). The Paf1 complex: platform or player in RNA poly-
merase II transcription? Biochim. Biophys. Acta 1799, 379–388.
Jiang, Y., Shen, H., Liu, X., Dai, J., Jin, G., Qin, Z., Chen, J.,Wang, S.,Wang, X.,
Hu, Z., and Shen, H. (2011). Genetic variants at 1p11.2 and breast cancer risk:
a two-stage study in Chinese women. PLoS ONE 6, e21563.
Jones, P.A. (2012). Functions of DNA methylation: islands, start sites, gene
bodies and beyond. Nat. Rev. Genet. 13, 484–492.
Juven-Gershon, T., and Kadonaga, J.T. (2010). Regulation of gene expression
via the core promoter and the basal transcriptional machinery. Dev. Biol. 339,
225–229.
Kagey, M.H., Newman, J.J., Bilodeau, S., Zhan, Y., Orlando, D.A., van
Berkum, N.L., Ebmeier, C.C., Goossens, J., Rahl, P.B., Levine, S.S., et al.
(2010). Mediator and cohesin connect gene expression and chromatin archi-
tecture. Nature 467, 430–435.
Kajimura, S., Seale, P., Kubota, K., Lunsford, E., Frangioni, J.V., Gygi, S.P.,
and Spiegelman, B.M. (2009). Initiation of myoblast to brown fat switch by
a PRDM16-C/EBP-beta transcriptional complex. Nature 460, 1154–1158.
Kapoor, A., Goldberg, M.S., Cumberland, L.K., Ratnakumar, K., Segura, M.F.,
Emanuel, P.O., Menendez, S., Vardabasso, C., Leroy, G., Vidal, C.I., et al.
(2010). The histone variant macroH2A suppresses melanoma progression
through regulation of CDK8. Nature 468, 1105–1109.
Kathiresan, S., and Srivastava, D. (2012). Genetics of human cardiovascular
disease. Cell 148, 1242–1257.
Kaufmann, R., Straussberg, R., Mandel, H., Fattal-Valevski, A., Ben-Zeev, B.,
Naamati, A., Shaag, A., Zenvirt, S., Konen, O., Mimouni-Bloch, A., et al. (2010).
Infantile cerebral and cerebellar atrophy is associated with a mutation in the
MED17 subunit of the transcription preinitiation mediator complex. Am. J.
Hum. Genet. 87, 667–670.
Kawauchi, S., Calof, A.L., Santos, R., Lopez-Burks,M.E., Young, C.M., Hoang,
M.P., Chua, A., Lao, T., Lechner, M.S., Daniel, J.A., et al. (2009). Multiple organ
system defects and transcriptional dysregulation in the Nipbl(+/-) mouse,
a model of Cornelia de Lange Syndrome. PLoS Genet. 5, e1000650.
Kim, T.K., Hemberg, M., Gray, J.M., Costa, A.M., Bear, D.M., Wu, J., Harmin,
D.A., Laptewicz, M., Barbara-Haley, K., Kuersten, S., et al. (2010). Widespread
transcription at neuronal activity-regulated enhancers. Nature 465, 182–187.
Kornberg, R.D. (2005). Mediator and the mechanism of transcriptional activa-
tion. Trends Biochem. Sci. 30, 235–239.
Kotake, Y., Nakagawa, T., Kitagawa, K., Suzuki, S., Liu, N., Kitagawa, M., and
Xiong, Y. (2011). Long non-coding RNA ANRIL is required for the PRC2 recruit-
ment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 30,
1956–1962.
Krivega, I., and Dean, A. (2012). Enhancer and promoter interactions-long
distance calls. Curr. Opin. Genet. Dev. 22, 79–85.
Kyewski, B., and Klein, L. (2006). A central role for central tolerance. Annu. Rev.
Immunol. 24, 571–606.
Larivie`re, L., Seizl, M., and Cramer, P. (2012). A structural perspective on
Mediator function. Curr. Opin. Cell Biol. 24, 305–313.
Latos, P.A., Pauler, F.M., Koerner, M.V., Sxenergin, H.B., Hudson, Q.J.,
Stocsits, R.R., Allhoff, W., Stricker, S.H., Klement, R.M., Warczok, K.E.,1248 Cell 152, March 14, 2013 ª2013 Elsevier Inc.et al. (2012). Airn transcriptional overlap, but not its lncRNA products, induces
imprinted Igf2r silencing. Science 338, 1469–1472.
Leal, A., Huehne, K., Bauer, F., Sticht, H., Berger, P., Suter, U., Morera, B., Del
Valle, G., Lupski, J.R., Ekici, A., et al. (2009). Identification of the variant
Ala335Val of MED25 as responsible for CMT2B2: molecular data, functional
studies of the SH3 recognition motif and correlation between wild-type
MED25 and PMP22 RNA levels in CMT1A animal models. Neurogenetics 10,
275–287.
Lee, J.T. (2012). Epigenetic regulation by long noncoding RNAs. Science 338,
1435–1439.
Lejeune, E., and Allshire, R.C. (2011). Common ground: small RNA program-
ming and chromatin modifications. Curr. Opin. Cell Biol. 23, 258–265.
Lelli, K.M., Slattery, M., and Mann, R.S. (2012). Disentangling the many layers
of eukaryotic transcriptional regulation. Annu. Rev. Genet. 46, 43–68.
Li, X.S., Trojer, P., Matsumura, T., Treisman, J.E., and Tanese, N. (2010).
Mammalian SWI/SNF—a subunit BAF250/ARID1 is an E3 ubiquitin ligase
that targets histone H2B. Mol. Cell. Biol. 30, 1673–1688.
Li, G., Ruan, X., Auerbach, R.K., Sandhu, K.S., Zheng, M., Wang, P., Poh,
H.M., Goh, Y., Lim, J., Zhang, J., et al. (2012). Extensive promoter-centered
chromatin interactions provide a topological basis for transcription regulation.
Cell 148, 84–98.
Lin, C., Smith, E.R., Takahashi, H., Lai, K.C., Martin-Brown, S., Florens, L.,
Washburn, M.P., Conaway, J.W., Conaway, R.C., and Shilatifard, A. (2010).
AFF4, a component of the ELL/P-TEFb elongation complex and a shared
subunit of MLL chimeras, can link transcription elongation to leukemia. Mol.
Cell 37, 429–437.
Lin, C., Garrett, A.S., De Kumar, B., Smith, E.R., Gogol, M., Seidel, C.,
Krumlauf, R., and Shilatifard, A. (2011). Dynamic transcriptional events in
embryonic stem cells mediated by the super elongation complex (SEC). Genes
Dev. 25, 1486–1498.
Lin, C.Y., Love´n, J., Rahl, P.B., Paranal, R.M., Burge, C.B., Bradner, J.E., Lee,
T.I., and Young, R.A. (2012). Transcriptional amplification in tumor cells with
elevated c-Myc. Cell 151, 56–67.
Littlewood, T.D., Kreuzaler, P., and Evan, G.I. (2012). All things to all people.
Cell 151, 11–13.
Liu, J., and Krantz, I.D. (2008). Cohesin and human disease. Annu. Rev.
Genomics Hum. Genet. 9, 303–320.
Liu, J., Zhang, Z., Bando, M., Itoh, T., Deardorff, M.A., Clark, D., Kaur, M.,
Tandy, S., Kondoh, T., Rappaport, E., et al. (2009). Transcriptional dysregula-
tion in NIPBL and cohesin mutant human cells. PLoS Biol. 7, e1000119.
Liu, G., Gramling, S., Munoz, D., Cheng, D., Azad, A.K., Mirshams, M., Chen,
Z., Xu, W., Roberts, H., Shepherd, F.A., et al. (2011). Two novel BRM insertion
promoter sequence variants are associated with loss of BRM expression and
lung cancer risk. Oncogene 30, 3295–3304.
Lubbe, S.J., Pittman, A.M., Olver, B., Lloyd, A., Vijayakrishnan, J., Naranjo, S.,
Dobbins, S., Broderick, P., Go´mez-Skarmeta, J.L., and Houlston, R.S. (2012).
The 14q22.2 colorectal cancer variant rs4444235 shows cis-acting regulation
of BMP4. Oncogene 31, 3777–3784.
Luo, Z., Lin, C., Guest, E., Garrett, A.S., Mohaghegh, N., Swanson, S.,
Marshall, S., Florens, L., Washburn, M.P., and Shilatifard, A. (2012a). The
super elongation complex family of RNA polymerase II elongation factors:
gene target specificity and transcriptional output. Mol. Cell. Biol. 32, 2608–
2617.
Luo, Z., Lin, C., and Shilatifard, A. (2012b). The super elongation complex
(SEC) family in transcriptional control. Nat. Rev. Mol. Cell Biol. 13, 543–547.
Maestro, M.A., Cardalda, C., Boj, S.F., Luco, R.F., Servitja, J.M., and Ferrer, J.
(2007). Distinct roles of HNF1beta, HNF1alpha, and HNF4alpha in regulating
pancreas development, beta-cell function and growth. Endocr. Dev. 12, 33–45.
Ma¨kinen, N., Heinonen, H.R., Moore, S., Tomlinson, I.P., van der Spuy, Z.M.,
and Aaltonen, L.A. (2011a). MED12 exon 2 mutations are common in uterine
leiomyomas from South African patients. Oncotarget 2, 966–969.
Ma¨kinen, N., Mehine, M., Tolvanen, J., Kaasinen, E., Li, Y., Lehtonen, H.J.,
Gentile, M., Yan, J., Enge, M., Taipale, M., et al. (2011b). MED12, the mediator
complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.
Science 334, 252–255.
Malecki, M.T. (2005). Genetics of type 2 diabetes mellitus. Diabetes Res. Clin.
Pract. 68(Suppl 1), S10–S21.
Malik, S., and Roeder, R.G. (2010). The metazoan Mediator co-activator
complex as an integrative hub for transcriptional regulation. Nat. Rev. Genet.
11, 761–772.
Mannini, L., and Musio, A. (2011). The dark side of cohesin: the carcinogenic
point of view. Mutat. Res. 728, 81–87.
Margueron, R., and Reinberg, D. (2011). The Polycomb complex PRC2 and its
mark in life. Nature 469, 343–349.
Marro, S., Pang, Z.P., Yang, N., Tsai, M.C., Qu, K., Chang, H.Y., Su¨dhof, T.C.,
and Wernig, M. (2011). Direct lineage conversion of terminally differentiated
hepatocytes to functional neurons. Cell Stem Cell 9, 374–382.
Marschalek, R. (2010). Mixed lineage leukemia: roles in human malignancies
and potential therapy. FEBS J. 277, 1822–1831.
Mathis, D., and Benoist, C. (2009). Aire. Annu. Rev. Immunol. 27, 287–312.
Maurano, M.T., Humbert, R., Rynes, E., Thurman, R.E., Haugen, E., Wang, H.,
Reynolds, A.P., Sandstrom, R., Qu, H., Brody, J., et al. (2012). Systematic
localization of common disease-associated variation in regulatory DNA.
Science 337, 1190–1195.
Metzger, T.C., and Anderson, M.S. (2011). Control of central and peripheral
tolerance by Aire. Immunol. Rev. 241, 89–103.
Mills, A.A. (2010). Throwing the cancer switch: reciprocal roles of polycomb
and trithorax proteins. Nat. Rev. Cancer 10, 669–682.
Moazed, D. (2009). Small RNAs in transcriptional gene silencing and genome
defence. Nature 457, 413–420.
Morris, E.J., Ji, J.Y., Yang, F., Di Stefano, L., Herr, A., Moon, N.S., Kwon, E.J.,
Haigis, K.M., Na¨a¨r, A.M., and Dyson, N.J. (2008). E2F1 represses beta-catenin
transcription and is antagonized by both pRB andCDK8. Nature 455, 552–556.
Nakajima, T., Inui, S., Fushimi, T., Noguchi, F., Kitagawa, Y., Reddy, J.K., and
Itami, S. (2013). Roles of MED1 in quiescence of hair follicle stem cells and
maintenance of normal hair cycling. J. Invest. Dermatol. 133, 354–360.
Ng, H.H., and Surani, M.A. (2011). The transcriptional and signalling networks
of pluripotency. Nat. Cell Biol. 13, 490–496.
Nguyen, D., Krueger, B.J., Sedore, S.C., Brogie, J.E., Rogers, J.T., Rajendra,
T.K., Saunders, A., Matera, A.G., Lis, J.T., Uguen, P., and Price, D.H. (2012).
The Drosophila 7SK snRNP and the essential role of dHEXIM in development.
Nucleic Acids Res. 40, 5283–5297.
Nicodeme, E., Jeffrey, K.L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.W.,
Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010). Suppression of
inflammation by a synthetic histone mimic. Nature 468, 1119–1123.
Nie, Z., Hu, G., Wei, G., Cui, K., Yamane, A., Resch, W., Wang, R., Green, D.R.,
Tessarollo, L., Casellas, R., et al. (2012). c-Myc is a universal amplifier of
expressed genes in lymphocytes and embryonic stem cells. Cell 151, 68–79.
Nowak, D.E., Tian, B., Jamaluddin, M., Boldogh, I., Vergara, L.A., Choudhary,
S., and Brasier, A.R. (2008). RelA Ser276 phosphorylation is required for
activation of a subset of NF-kappaB-dependent genes by recruiting cyclin-
dependent kinase 9/cyclin T1 complexes. Mol. Cell. Biol. 28, 3623–3638.
Oda, Y., Hu, L., Bul, V., Elalieh, H., Reddy, J.K., and Bikle, D.D. (2012). Coac-
tivator MED1 ablation in keratinocytes results in hair-cycling defects and
epidermal alterations. J. Invest. Dermatol. 132, 1075–1083.
Odom, D.T., Zizlsperger, N., Gordon, D.B., Bell, G.W., Rinaldi, N.J., Murray,
H.L., Volkert, T.L., Schreiber, J., Rolfe, P.A., Gifford, D.K., et al. (2004). Control
of pancreas and liver gene expression by HNF transcription factors. Science
303, 1378–1381.
Ong, C.T., and Corces, V.G. (2011). Enhancer function: new insights into the
regulation of tissue-specific gene expression. Nat. Rev. Genet. 12, 283–293.
Orkin, S.H., and Hochedlinger, K. (2011). Chromatin connections to pluripo-
tency and cellular reprogramming. Cell 145, 835–850.
Orom, U.A., and Shiekhattar, R. (2011). Noncoding RNAs and enhancers:
complications of a long-distance relationship. Trends Genet. 27, 433–439.Oven, I., Brdickova´, N., Kohoutek, J., Vaupotic, T., Narat, M., and Peterlin,
B.M. (2007). AIRE recruits P-TEFb for transcriptional elongation of target
genes in medullary thymic epithelial cells. Mol. Cell. Biol. 27, 8815–8823.
Pang, Z.P., Yang, N., Vierbuchen, T., Ostermeier, A., Fuentes, D.R., Yang,
T.Q., Citri, A., Sebastiano, V., Marro, S., Su¨dhof, T.C., and Wernig, M.
(2011). Induction of human neuronal cells by defined transcription factors.
Nature 476, 220–223.
Panne, D. (2008). The enhanceosome. Curr. Opin. Struct. Biol. 18, 236–242.
Papageorgiou, N., Tousoulis, D., Androulakis, E., Siasos, G., Briasoulis, A.,
Vogiatzi, G., Kampoli, A.M., Tsiamis, E., Tentolouris, C., and Stefanadis, C.
(2012). The role of microRNAs in cardiovascular disease. Curr. Med. Chem.
19, 2605–2610.
Parelho, V., Hadjur, S., Spivakov, M., Leleu, M., Sauer, S., Gregson, H.C.,
Jarmuz, A., Canzonetta, C., Webster, Z., Nesterova, T., et al. (2008). Cohesins
functionally associate with CTCF on mammalian chromosome arms. Cell 132,
422–433.
Park, K.S., Cha, Y., Kim, C.H., Ahn, H.J., Kim, D., Ko, S., Kim, K.H., Chang,
M.Y., Ko, J.H., Noh, Y.S., et al. (2013). Transcription elongation factor tcea3
regulates the pluripotent differentiation potential of mouse embryonic stem
cells via the lefty1-nodal-smad2 pathway. Stem Cells 31, 282–292.
Pasmant, E., Sabbagh, A., Vidaud, M., and Bie`che, I. (2011). ANRIL, a long,
noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 25,
444–448.
Philibert, R.A., Bohle, P., Secrest, D., Deaderick, J., Sandhu, H., Crowe, R.,
and Black, D.W. (2007). The association of the HOPA(12bp) polymorphism
with schizophrenia in the NIMH Genetics Initiative for Schizophrenia sample.
Am. J. Med. Genet. B. Neuropsychiatr. Genet. 144B, 743–747.
Phillips, J.E., and Corces, V.G. (2009). CTCF: master weaver of the genome.
Cell 137, 1194–1211.
Popov, N., and Gil, J. (2010). Epigenetic regulation of the INK4b-ARF-INK4a
locus: in sickness and in health. Epigenetics 5, 685–690.
Rahl, P.B., Lin, C.Y., Seila, A.C., Flynn, R.A., McCuine, S., Burge, C.B., Sharp,
P.A., and Young, R.A. (2010). c-Myc regulates transcriptional pause release.
Cell 141, 432–445.
Rando, O.J. (2012). Combinatorial complexity in chromatin structure and func-
tion: revisiting the histone code. Curr. Opin. Genet. Dev. 22, 148–155.
Reyes-Turcu, F.E., and Grewal, S.I. (2012). Different means, same end-hetero-
chromatin formation by RNAi and RNAi-independent RNA processing factors
in fission yeast. Curr. Opin. Genet. Dev. 22, 156–163.
Rinn, J.L., and Chang, H.Y. (2012). Genome regulation by long noncoding
RNAs. Annu. Rev. Biochem. 81, 145–166.
Risheg, H., Graham, J.M., Jr., Clark, R.D., Rogers, R.C., Opitz, J.M.,
Moeschler, J.B., Peiffer, A.P., May, M., Joseph, S.M., Jones, J.R., et al.
(2007). A recurrent mutation in MED12 leading to R961W causes Opitz-
Kaveggia syndrome. Nat. Genet. 39, 451–453.
Roeder, R.G. (2005). Transcriptional regulation and the role of diverse coacti-
vators in animal cells. FEBS Lett. 579, 909–915.
Roger, V.L., Go, A.S., Lloyd-Jones, D.M., Benjamin, E.J., Berry, J.D., Borden,
W.B., Bravata, D.M., Dai, S., Ford, E.S., Fox, C.S., et al.; American Heart Asso-
ciation Statistics Committee and Stroke Statistics Subcommittee. (2012).
Executive summary: heart disease and stroke statistics—2012 update: a report
from the American Heart Association. Circulation 125, 188–197.
Rump, P., Niessen, R.C., Verbruggen, K.T., Brouwer, O.F., de Raad, M., and
Hordijk, R. (2011). A novel mutation in MED12 causes FG syndrome (Opitz-
Kaveggia syndrome). Clin. Genet. 79, 183–188.
Sanda, T., Lawton, L.N., Barrasa, M.I., Fan, Z.P., Kohlhammer, H., Gutierrez,
A., Ma,W., Tatarek, J., Ahn, Y., Kelliher, M.A., et al. (2012). Core transcriptional
regulatory circuit controlled by the TAL1 complex in human T cell acute
lymphoblastic leukemia. Cancer Cell 22, 209–221.
Santen, G.W., Aten, E., Sun, Y., Almomani, R., Gilissen, C., Nielsen, M., Kant,
S.G., Snoeck, I.N., Peeters, E.A., Hilhorst-Hofstee, Y., et al. (2012a). Mutations
in SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris
syndrome. Nat. Genet. 44, 379–380.Cell 152, March 14, 2013 ª2013 Elsevier Inc. 1249
Santen, G.W., Kriek, M., and van Attikum, H. (2012b). SWI/SNF complex in
disorder: SWItching from malignancies to intellectual disability. Epigenetics
7, 1219–1224.
Schaaf, C.A., Misulovin, Z., Sahota, G., Siddiqui, A.M., Schwartz, Y.B., Kahn,
T.G., Pirrotta, V., Gause, M., and Dorsett, D. (2009). Regulation of the
Drosophila Enhancer of split and invected-engrailed gene complexes by sister
chromatid cohesion proteins. PLoS ONE 4, e6202.
Schmidt, D., Schwalie, P.C., Ross-Innes, C.S., Hurtado, A., Brown, G.D.,
Carroll, J.S., Flicek, P., and Odom, D.T. (2010). A CTCF-independent role for
cohesin in tissue-specific transcription. Genome Res. 20, 578–588.
Schodel, J., Bardella, C., Sciesielski, L.K., Brown, J.M., Pugh, C.W., Buckle,
V., Tomlinson, I.P., Ratcliffe, P.J., and Mole, D.R. (2012). Common genetic
variants at the 11q13.3 renal cancer susceptibility locus influence binding
of HIF to an enhancer of cyclin D1 expression. Nat. Genet. 44, 420–425,
S421–422.
Schwartz, C.E., Tarpey, P.S., Lubs, H.A., Verloes, A., May, M.M., Risheg, H.,
Friez, M.J., Futreal, P.A., Edkins, S., Teague, J., et al. (2007). The original Lujan
syndrome family has a novel missense mutation (p.N1007S) in the MED12
gene. J. Med. Genet. 44, 472–477.
Seal, R.L., Gordon, S.M., Lush, M.J., Wright, M.W., and Bruford, E.A.
(2011). genenames.org: the HGNC resources in 2011. Nucleic Acids Res.
39(Database issue), D514–D519.
Seitan, V.C., andMerkenschlager, M. (2012). Cohesin and chromatin organisa-
tion. Curr. Opin. Genet. Dev. 22, 93–100.
Seitan, V.C., Hao, B., Tachibana-Konwalski, K., Lavagnolli, T., Mira-Bonten-
bal, H., Brown, K.E., Teng, G., Carroll, T., Terry, A., Horan, K., et al. (2011). A
role for cohesin in T-cell-receptor rearrangement and thymocyte differentia-
tion. Nature 476, 467–471.
Sekiya, S., and Suzuki, A. (2011). Direct conversion of mouse fibroblasts to
hepatocyte-like cells by defined factors. Nature 475, 390–393.
Sigova, A.A., Mullen, A.C., Moline, B., Gupta, S., Orlando, D.A., Guenther,
M.G., Almada, A.A., Lin, C., Burge, C.B., Sharp, P.A., et al. (2013). Divergent
transcription of long noncoding RNA/mRNA gene pairs in embryonic stem
cells. Proc. Natl. Acad. Sci. USA. 110, 2876–2881.
Sikorski, T.W., and Buratowski, S. (2009). The basal initiation machinery:
beyond the general transcription factors. Curr. Opin. Cell Biol. 21, 344–351.
Slany, R.K. (2009). The molecular biology of mixed lineage leukemia.
Haematologica 94, 984–993.
Small, E.M., and Olson, E.N. (2011). Pervasive roles of microRNAs in cardio-
vascular biology. Nature 469, 336–342.
Smith, E., Lin, C., and Shilatifard, A. (2011a). The super elongation complex
(SEC) and MLL in development and disease. Genes Dev. 25, 661–672.
Smith, E.R., Lin, C., Garrett, A.S., Thornton, J., Mohaghegh, N., Hu, D.,
Jackson, J., Saraf, A., Swanson, S.K., Seidel, C., et al. (2011b). The little
elongation complex regulates small nuclear RNA transcription. Mol. Cell 44,
954–965.
Spaeth, J.M., Kim, N.H., and Boyer, T.G. (2011). Mediator and human disease.
Semin. Cell Dev. Biol. 22, 776–787.
Spitz, F., and Furlong, E.E. (2012). Transcription factors: from enhancer
binding to developmental control. Nat. Rev. Genet. 13, 613–626.
Taatjes, D.J. (2010). The human Mediator complex: a versatile, genome-wide
regulator of transcription. Trends Biochem. Sci. 35, 315–322.
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells
from mouse embryonic and adult fibroblast cultures by defined factors. Cell
126, 663–676.
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo,
P., Just, S., Rottbauer, W., Frantz, S., et al. (2008). MicroRNA-21 contributes
to myocardial disease by stimulating MAP kinase signalling in fibroblasts.
Nature 456, 980–984.
Thurman, R.E., Rynes, E., Humbert, R., Vierstra, J., Maurano, M.T.,
Haugen, E., Sheffield, N.C., Stergachis, A.B., Wang, H., Vernot, B., et al.1250 Cell 152, March 14, 2013 ª2013 Elsevier Inc.(2012). The accessible chromatin landscape of the human genome. Nature
489, 75–82.
Tsai, H.C., and Baylin, S.B. (2011). Cancer epigenetics: linking basic biology to
clinical medicine. Cell Res. 21, 502–517.
Tsurusaki, Y., Okamoto, N., Ohashi, H., Kosho, T., Imai, Y., Hibi-Ko, Y.,
Kaname, T., Naritomi, K., Kawame, H., Wakui, K., et al. (2012). Mutations
affecting components of the SWI/SNF complex cause Coffin-Siris syndrome.
Nat. Genet. 44, 376–378.
Van Houdt, J.K., Nowakowska, B.A., Sousa, S.B., van Schaik, B.D., Seuntjens,
E., Avonce, N., Sifrim, A., Abdul-Rahman, O.A., van den Boogaard, M.J.,
Bottani, A., et al. (2012). Heterozygous missense mutations in SMARCA2
cause Nicolaides-Baraitser syndrome. Nat. Genet. 44, 445–449, S441.
van Rooij, E., Sutherland, L.B., Qi, X., Richardson, J.A., Hill, J., and Olson, E.N.
(2007). Control of stress-dependent cardiac growth and gene expression by
a microRNA. Science 316, 575–579.
van Rooij, E., Sutherland, L.B., Thatcher, J.E., DiMaio, J.M., Naseem, R.H.,
Marshall, W.S., Hill, J.A., and Olson, E.N. (2008). Dysregulation of microRNAs
after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc.
Natl. Acad. Sci. USA 105, 13027–13032.
Vierbuchen, T., Ostermeier, A., Pang, Z.P., Kokubu, Y., Su¨dhof, T.C., and
Wernig, M. (2010). Direct conversion of fibroblasts to functional neurons by
defined factors. Nature 463, 1035–1041.
Wang, D., Garcia-Bassets, I., Benner, C., Li, W., Su, X., Zhou, Y., Qiu, J., Liu,
W., Kaikkonen, M.U., Ohgi, K.A., et al. (2011). Reprogramming transcription
by distinct classes of enhancers functionally defined by eRNA. Nature 474,
390–394.
Wendt, K.S., Yoshida, K., Itoh, T., Bando, M., Koch, B., Schirghuber, E.,
Tsutsumi, S., Nagae, G., Ishihara, K., Mishiro, T., et al. (2008). Cohesin
mediates transcriptional insulation by CCCTC-binding factor. Nature 451,
796–801.
Wilson, B.G., and Roberts, C.W. (2011). SWI/SNF nucleosome remodellers
and cancer. Nat. Rev. Cancer 11, 481–492.
Wright, J.E., and Ciosk, R. (2013). RNA-based regulation of pluripotency.
Trends Genet. 29, 99–107.
Xie, H., Ye, M., Feng, R., and Graf, T. (2004). Stepwise reprogramming of B
cells into macrophages. Cell 117, 663–676.
Xu, H., Tomaszewski, J.M., and McKay, M.J. (2011). Can corruption of chro-
mosome cohesion create a conduit to cancer? Nat. Rev. Cancer 11, 199–210.
Yamanaka, S. (2012). Induced pluripotent stem cells: past, present, and future.
Cell Stem Cell 10, 678–684.
Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., Zhang, Y., Xu, C., Bai, Y.,Wang,
H., et al. (2007). The muscle-specific microRNA miR-1 regulates cardiac
arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat. Med. 13,
486–491.
Yankulov, K., Blau, J., Purton, T., Roberts, S., and Bentley, D.L. (1994). Tran-
scriptional elongation by RNA polymerase II is stimulated by transactivators.
Cell 77, 749–759.
Yap, K.L., Li, S., Mun˜oz-Cabello, A.M., Raguz, S., Zeng, L., Mujtaba, S., Gil, J.,
Walsh, M.J., and Zhou,M.M. (2010). Molecular interplay of the noncoding RNA
ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcrip-
tional silencing of INK4a. Mol. Cell 38, 662–674.
Yeo, J.C., and Ng, H.H. (2013). The transcriptional regulation of pluripotency.
Cell Res. 23, 20–32.
Yew, P.Y., Mushiroda, T., Kiyotani, K., Govindasamy, G.K., Yap, L.F., Teo,
S.H., Lim, P.V., Govindaraju, S., Ratnavelu, K., Sam, C.K., et al.; Malaysian
NPC Study Group. (2012). Identification of a functional variant in SPLUNC1
associated with nasopharyngeal carcinoma susceptibility among Malaysian
Chinese. Mol. Carcinog. 51(Suppl 1), E74–E82.
Young, R.A. (2011). Control of the embryonic stemcell state.Cell 144, 940–954.
Zhao, J.Y., Yang, X.Y., Gong, X.H., Gu, Z.Y., Duan, W.Y., Wang, J., Ye, Z.Z.,
Shen, H.B., Shi, K.H., Hou, J., et al. (2012). Functional variant in methionine
synthase reductase intron-1 significantly increases the risk of congenital heart
disease in the Han Chinese population. Circulation 125, 482–490.
Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J., andMelton, D.A. (2008). In vivo
reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 455,
627–632.
Zhou, H., Spaeth, J.M., Kim, N.H., Xu, X., Friez, M.J., Schwartz, C.E., and
Boyer, T.G. (2012a). MED12 mutations link intellectual disability syndromes
with dysregulated GLI3-dependent Sonic Hedgehog signaling. Proc. Natl.
Acad. Sci. USA 109, 19763–19768.Zhou, Q., Li, T., and Price, D.H. (2012b). RNA polymerase II elongation control.
Annu. Rev. Biochem. 81, 119–143.
Zhu, J., Adli, M., Zou, J.Y., Verstappen, G., Coyne, M., Zhang, X., Durham, T.,
Miri, M., Deshpande, V., De Jager, P.L., et al. (2013). Genome-wide chromatin
state transitions associated with developmental and environmental cues. Cell
152, 642–654.
Zumer, K., Plemenitas, A., Saksela, K., and Peterlin, B.M. (2011). Patient muta-
tion in AIRE disrupts P-TEFb binding and target gene transcription. Nucleic
Acids Res. 39, 7908–7919.Cell 152, March 14, 2013 ª2013 Elsevier Inc. 1251
